Amplia Therapeutics (ASX:ATX) Beginning Cash Position: A$29.16 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:ATX Amplia Therapeutics Ltd ASX:ATX
33 GF Score
Price A$0.14
! 2 Warning Signs
View Full Analysis

What is Amplia Therapeutics Beginning Cash Position?

Amplia Therapeutics ASX:ATX 33 Beginning Cash Position is A$29.16 Mil as of Mar. 2026. GuruFocus rates ASX:ATX with a GF Score™ of 33/100. The stock has 2 warning signs investors should review.

Amplia Therapeutics's Beginning Cash Position for the quarter that ended in Mar. 2026 was A$29.16 Mil.

Amplia Therapeutics's quarterly Beginning Cash Position increased from Mar. 2025 (A$4.56 Mil) to Sep. 2025 (A$10.86 Mil) and increased from Sep. 2025 (A$10.86 Mil) to Mar. 2026 (A$29.16 Mil).

Amplia Therapeutics's annual Beginning Cash Position declined from Mar. 2024 (A$9.26 Mil) to Mar. 2025 (A$3.39 Mil) but then increased from Mar. 2025 (A$3.39 Mil) to Mar. 2026 (A$10.86 Mil).

Amplia Therapeutics Beginning Cash Position Related Terms

Amplia Therapeutics Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Amplia Therapeutics's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amplia Therapeutics Beginning Cash Position Chart

Amplia Therapeutics Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.85 14.61 9.26 3.39 10.86

Amplia Therapeutics Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.65 3.38 4.56 10.86 29.16
ASX:ATX
33GF Score
Amplia Therapeutics Ltd ASX:ATX
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Amplia Therapeutics Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of A$29.16 Mil mean?
Amplia Therapeutics (ASX:ATX) has a Beginning Cash Position of A$29.16 Mil as of Mar. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Amplia Therapeutics and its competitors.
Is Amplia Therapeutics' Beginning Cash Position too high?
Amplia Therapeutics' current Beginning Cash Position is A$29.16 Mil. Overall, Amplia Therapeutics has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Amplia Therapeutics' Beginning Cash Position compare to VRTX and REGN?
Amplia Therapeutics' Beginning Cash Position of A$29.16 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Amplia Therapeutics and its competitors. Amplia Therapeutics's current Beginning Cash Position is A$29.16 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amplia Therapeutics stock overvalued right now?
Amplia Therapeutics (ASX:ATX) has a current Beginning Cash Position of A$29.16 Mil. The current Beginning Cash Position is A$29.16 Mil. Amplia Therapeutics' overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Amplia Therapeutics (ASX:ATX), the current Beginning Cash Position is A$29.16 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Amplia Therapeutics Business Description

Other Exchanges INNMF:USA
Address 90 William Street, Level 5, Melbourne, VIC, AUS, 3000
Amplia Therapeutics Ltd is an Australian, clinical-stage, drug development company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. The company is focused on the development of these drug candidates for potential use in multiple indications in oncology (e.g. pancreatic cancer) and chronic fibrotic diseases. Its molecule, AMP945 is a selective and potent inhibitor of FAK and is currently in a phase 2 clinical trial for pancreatic cancer, in clinical development for ovarian cancer, and preclinical development for idiopathic pulmonary fibrosis (IPF).
33GF Score

Get the complete analysis for ASX:ATX

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.14
Price